The safety of available treatments options for neuroendocrine tumors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of available treatments options for neuroendocrine tumors
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 16, Issue 10, Pages 1149-1161
Publisher
Informa UK Limited
Online
2017-07-14
DOI
10.1080/14740338.2017.1354984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
- (2017) Rocio Garcia-Carbonero et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radionuclide Therapy for Neuroendocrine Tumors
- (2017) Mauro Cives et al. Current Oncology Reports
- Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors
- (2016) Daniela Mueller et al. BMC CANCER
- Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
- (2016) Kjell Öberg et al. ENDOCRINE-RELATED CANCER
- Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
- (2016) Dik J. Kwekkeboom et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
- (2016) R. Garcia-Carbonero et al. NEUROENDOCRINOLOGY
- Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature
- (2016) Antongiulio Faggiano et al. ONCOLOGIST
- [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
- (2016) Richard P. Baum et al. Theranostics
- Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
- (2015) Jaume Capdevila et al. BMC CANCER
- Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series
- (2015) Hiroo Imai et al. CHEMOTHERAPY
- Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
- (2015) J. Hadoux et al. ENDOCRINE-RELATED CANCER
- Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity
- (2015) Pantelis Clewemar Antonodimitrakis et al. NEUROENDOCRINOLOGY
- Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
- (2015) Michael S Broder WORLD JOURNAL OF GASTROENTEROLOGY
- Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
- (2015) Edward Wolin et al. Drug Design Development and Therapy
- Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours
- (2014) Tim Meyer et al. EUROPEAN JOURNAL OF CANCER
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
- (2014) Giovanni Paganelli et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
- (2013) Robert L. Fine et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
- (2013) Edward M. Wolin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
- (2013) Federica Barbieri et al. DRUG DISCOVERY TODAY
- Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas
- (2013) Z. H. Lu et al. MEDICAL ONCOLOGY
- Treatment with the Radiolabelled Somatostatin Analog177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- (2013) Maddalena Sansovini et al. NEUROENDOCRINOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
- (2012) O Hentic et al. ENDOCRINE-RELATED CANCER
- Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
- (2012) Tetsuhide Ito et al. INVESTIGATIONAL NEW DRUGS
- Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas
- (2012) K. Nakano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
- (2012) Ingrid H. Olsen et al. TheScientificWorldJOURNAL
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy
- (2011) Corinne Bousquet et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
- (2011) Andreas Klaus Pfeifer et al. NEUROENDOCRINOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review
- (2010) Lutfun Nisa et al. ANNALS OF NUCLEAR MEDICINE
- Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
- (2010) N C Turner et al. BRITISH JOURNAL OF CANCER
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
- (2010) S. Iwasa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- (2010) David L. Bushnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
- (2009) J. B. Cwikla et al. ANNALS OF ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
- (2008) Bart de Keizer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study
- (2008) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now